Veru Inc. (VERU)
NASDAQ: VERU · Real-Time Price · USD
0.649
+0.020 (3.20%)
At close: Dec 20, 2024, 4:00 PM
0.670
+0.021 (3.20%)
After-hours: Dec 20, 2024, 7:36 PM EST
Veru Inc. Employees
Veru Inc. had 189 employees as of September 30, 2023. The number of employees decreased by 44 or -18.88% compared to the previous year.
Employees
189
Change (1Y)
-44
Growth (1Y)
-18.88%
Revenue / Employee
$89,346
Profits / Employee
-$200,008
Market Cap
95.02M
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| MultiPlan | 2,800 |
| FONAR | 520 |
| Harvard Bioscience | 416 |
| Exagen | 179 |
| Century Therapeutics | 165 |
| Assembly Biosciences | 65 |
| Avalo Therapeutics | 19 |
| INmune Bio | 17 |
VERU News
- 25 days ago - Veru to Present at the 17th International Conference of the Society on Sarcopenia, Cachexia, & Wasting Disorders - GlobeNewsWire
- 6 weeks ago - Veru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which Supports Potential for Enobosarm to Optimize Weight Loss at ObesityWeek - GlobeNewsWire
- 2 months ago - Veru to Present at ObesityWeek: Meta-Analysis of 4 Previous Randomized Clinical Trials that Support the Potential of Enobosarm to Optimize Weight Loss - GlobeNewsWire
- 2 months ago - Veru to Deliver Keynote Presentation on the Scientific Support for Enobosarm in Combination with GLP-1 Receptor Agonist to Preserve Muscle for Higher Quality Weight Loss at the 4th Edition of the World Obesity and Weight Management Congress - GlobeNewsWire
- 3 months ago - Veru to Present at the 2024 Cantor Global Healthcare Conference - GlobeNewsWire
- 4 months ago - Veru Inc. (VERU) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Veru Reaches Full Enrollment for Phase 2b QUALITY Clinical Study of Enobosarm for Obesity and Reports Fiscal 2024 Third Quarter Financial Results - GlobeNewsWire
- 5 months ago - Veru to Report Fiscal 2024 Third Quarter Financial Results on August 8, 2024 - GlobeNewsWire